CallThemOut
Posted - 1 day ago
$ALT $VKTX $TERN $GUTS $GPCR Shorts are so fucked, keep your shares in non margin accounts and/or ensure your shares aren't lent.
Cost of WL drugs is about 1000/mo
Cost of Rezdiffra $5000/mo
Cost of MAFLD? Nothing approved on the market yet.
Cost of P3 for Obesity is 10x the cost of MAFLD and MASH due to the number of patients and duration of the study.
Overlap of Obesity, MAFLD, MASH is very high. Snorting coke and shorting a Co is going to cost the MFs good, let's make it painful for them.
Don't lend your shares.
Do not buy calls
Buy common stock or better still sell puts deep in the money and let them bleed even more money while you collect interest on their money and your blocked cash. Gives you the same maximum upside, but you collect additional interest while you wait. Burn the MF coke snorting short. They should never be allowed to target companies on faulty analysis and flawed thinking and hurt innovation in our country.
CallThemOut
Posted - 1 day ago
$ALT $VKTX $TERN $GUTS $GPCR Did I ask a question, or did you post your highly educated analysis and tried to prove something negative about Altimmune and the management publishing fictional or bad numbers?
Your theory and analysis demonstrated how little you understand and yet you think you are smarter than everyone else, including the management and statisticians working for Altimmune.
The hurt must be painful because you were so sure and posted everything your smart brain futured out, and now you are refusing to let go and eat the humble pie.
tttggg
Posted - 1 day ago
@lowfloatscambuster baker bros bet on $GPCR not vktx; perceptive increased shares Q3
tttggg
Posted - 1 day ago
$VKTX look at $GPCR … beautiful rebound
Lixothetinman
Posted - 2 days ago
$GPCR when KFC, Oops I mean JFK Junior starts Americans on eating foods fried in tallow,they'll need to double down on the drugs $VKTX , $ALT and $GPCR are developing. This drop is a manufactured political issue and is only temporary.
Quantumup
Posted - 2 days ago
BMO Capital defends its Obesity names $LLY $NVO $AMGN $GPCR, says Step Away From the Computer and Breathe - RFK Jr. Comments Are Not End of GLP-1s 📝while RFK Jr. appears less optimistic on incretins, he remains limited in his ability2influence either policy or pricing: $VKTX TERN XBI
kdtweet66
Posted - 2 days ago
$GPCR What is the news here? Why such a drop? Thx
DAR2487
Posted - 2 days ago
$GPCR bought a touch soon but it's a good starter.
BullYa
Posted - 2 days ago
$GPCR shorts are given you a cheap price to load it up.✅😂
BullYa
Posted - 3 days ago
$GPCR now looks like it’s very good price for starters or add more if you can right here. ✅
Sam201
Posted - 3 days ago
$GPCR still here n waiting for 20!
CallThemOut
Posted - 4 days ago
$ALT $VKTX $GPCR We are assuming too much. It is simpler
Big pharma are trying to show the street they can do it internally, the longer they wait $ALT, $VKTX , $GPCR and continue to spend their money, develop their drugs further, BPs are happy wait for as much details to cherry pick. $ALT is pushing hard to show weight loss along with a terrific metabolic drug. They looked at what semaglutide and others are being tested for and did an analysis on IMPACT & other studies data (smart to collect detailed data in all their trials). Whatever benefits could be showcased are put in the P3 design. It is nothing more, it is designed for a marketing label from the get-go. They are in no rush to move Pemvidutide WL to market. A smaller, less expensive quicker trial can get the same doses of Pemvi to market for MAFLD/MASH along with WL, and they can get a chunk of both markets. It's a game of chicken. Viking trials are designed for investors. Who gets BO first?
Lixothetinman
Posted - 5 days ago
$GPCR if only Alt could announce that partnership so I could sell and add to GPCR and $VKTX . These prices are a bargain.
BullYa
Posted - 5 days ago
$GPCR welcome to $30 🤗
DAR2487
Posted - 5 days ago
$GPCR it will be interesting how much say RFK Jr really has in the weight loss drug industry but for right now it appears to be a great time to load up on speculation
Lixothetinman
Posted - 6 days ago
$GPCR 42 to 44 incoming.
EPR53167
Posted - 6 days ago
$GPCR Anyone who didn’t load up this morning will - IMHO - regret it immensely pretty soon.
EPR53167
Posted - 1 week ago
$GPCR And she’s Green! A literal gift this am.
EPR53167
Posted - 1 week ago
$GPCR Loaded up on the $34 break…
Elevator_up
Posted - 1 week ago
$GPCR $VKTX Just a reminder of this 👇👇
biolover
Posted - 1 week ago
$VKTX $GPCR if shorts are serious about manufacturing issue, you would have seen structure SP exploding, but there is enormous pressure on structure by Viking oral outstanding data. All this manufacturing gossip is a hoax. They are using their cash power to suppress Viking given its small size and their big loss , but just for a short while.
Lixothetinman
Posted - 1 week ago
@MRTunity agreed. I own 3, $GPCR $ALT and $VKTX . This market has tremendous room for 3. To crap on one and favor another is just dumb with the stellar results each offer.
Personally, I own more shares in Alt, but only because there is more possible profit.
THECORLEONEFAMILY
Posted - 1 week ago
$GPCR When is the next ER?
DAR2487
Posted - 1 week ago
$GPCR in here
biolover
Posted - 1 week ago
$GPCR $VKTX
metalcook
Posted - 1 week ago
$GPCR Is probably taken out against January. If this happens than that means big pharma favors small molecules and should boost $TERN. SO $TERN is easy play (if patent is not a problem)
metalcook
Posted - 1 week ago
Most straight forward play ars $GPCR and $TERN.. $TERN hammered because of unclear patent problem. If this is cleared out should be worth a double at least as it's attractive to partner or take over (see AZN deal with Eccogene).
norbertm
Posted - 2 weeks ago
$SRM Funny this has a much more active ST board than a company like $GPCR or $CAR. What gives???
biolover
Posted - 2 weeks ago
$VKTX $GPCR some confused analysts claim structure medicine will be second to market with oral after Lilly. Structure and Viking staring phase 2 for oral meds at same time by 2024 year end. Viking will run 13 wk trial and proceed quickly to phase 3 in 2025 based on peptide safety and experience with FDA re sc formula of same drug . Structure plans to run 26 wk trial and go through extensive FDA scrutiny for toxicity related to small molecules particular liver toxicity then in best case scenario start phase 3 in 2026.